Abstract: This study suggests that the combination of Ph with radiotherapy exhibits promising activity against lung cancer, potentially through mechanisms including inhibition of glucose transport and promotion of apoptosis. These findings may provide a new therapeutic strategy for improving lung cancer treatment.
Introduction
Lung cancer remains the leading cause of cancer-related mortality worldwide. While radiotherapy is a cornerstone treatment, its efficacy is frequently limited by radioresistance—a state where cancer cells adapt to survive radiation-induced damage. To overcome this challenge, researchers are investigating radiosensitizers: compounds that increase the vulnerability of cancer cells to radiation without introducing significant systemic toxicity.
Phloretin (Ph), a natural polyphenol found in apple peels, has demonstrated anti-tumor effects in various cancers by inhibiting glucose transporters (GLUT) and disrupting the Warburg effect, effectively starving cancer cells of energy. This study explores Phloretin's potential as a radiosensitizer in lung cancer, investigating whether it can weaken cancer cells sufficiently to enhance the lethality of standard radiotherapy.
Methods and Materials
The researchers evaluated the combination of Phloretin and radiotherapy using both in vitro and in vivo models:
- In Vitro Assays: Lewis lung carcinoma (LLC) cells were treated with varying concentrations of Phloretin (0–200 µg/ml). MTT assays were employed to measure cell proliferation over 12, 24, and 36 hours. Additionally, colony-forming assays assessed cell survival following radiation doses ranging from 2 to 10 Gy, with and without Phloretin pretreatment.
- In Vivo Xenograft Models: C57BL/6 mice were injected with LLC cells to establish tumors. The mice were divided into four experimental groups: control, Phloretin alone (20 mg/kg), radiotherapy alone (10 Gy), and a combination group.
- Evaluation Metrics: Tumor volume and mouse survival were tracked over time. $^{18}$F-FDG PET/CT imaging was utilized to measure glucose uptake in live tumors. Post-mortem analysis included flow cytometry to quantify apoptosis and immunohistochemistry to assess Ki-67 expression, a marker of cell proliferation.
Key Results
The study demonstrated that Phloretin significantly enhances the therapeutic effects of radiotherapy across several key metrics:
- Enhanced Tumor Inhibition: In mouse models, the combination therapy achieved a 74.44% tumor inhibition rate, markedly higher than radiotherapy alone (59.33%) or Phloretin alone (38.99%).
- Prolonged Survival: The median survival time for the combination group was 56 days, a significant extension compared to 36 days for radiotherapy alone and 25 days for the control group ($p < 0.01$).
- Reduced Glucose Metabolism: $^{18}$F-FDG PET/CT scans revealed that the combination group had the lowest glucose uptake, with a mean SUVmax of 2.05, compared to 3.15 for radiotherapy alone and 5.51 for Phloretin alone.
- Increased Apoptosis and Reduced Proliferation: Flow cytometry showed that apoptosis rates reached 39.36% in the combination group. Concurrently, the percentage of actively proliferating cells (Ki-67 positive) dropped to just 8.35%, compared to 45.29% in the control group.
Discussion and Insights
The findings suggest that Phloretin acts as a potent radiosensitizer by inducing metabolic starvation in cancer cells. Radiotherapy causes DNA damage that requires significant energy (ATP) to repair. By inhibiting glucose transport, Phloretin deprives irradiated cells of the fuel required for these repair mechanisms, leading to increased cell death. This synergistic effect results in significantly higher apoptosis rates than either treatment alone.
As a naturally occurring dietary flavonoid, Phloretin represents a promising, low-toxicity candidate for clinical development as a radiotherapy adjuvant. However, the study's reliance on a single murine cell line (LLC) necessitates further validation in diverse human lung cancer models. Future research should also focus on mapping the exact molecular pathways disrupted by Phloretin to fully understand its mechanism of action in radiosensitization.
Summary updated